Low-grade myofibroblastic sarcoma (LGMS) is a subtype of the malignant sarcomas.[1] As it is currently recognized, LGMS was first described as a rare, atypical myofibroblastic tumor (i.e. a tumor consisting of cells with the microscopic features of fibroblasts and smooth muscle cells) by Mentzel et al. in 1998.[2] Myofibroblastic sarcomas had been divided into low-grade myofibroblastic sarcomas, intermediate‐grade myofibroblasic sarcomas, i.e. IGMS, and high‐grade myofibroblasic sarcomas, i.e. HGMS (also termed undifferentiated pleomorphic sarcoma and pleomorphic myofibrosarcoma [and formerly termed malignant fibrous histiocytoma[3]]) based on their microscopic morphological, immunophenotypic, and malignancy features.[4] LGMS and IGMS are now classified together[5] by the World Health Organization (WHO), 2020, in the category of intermediate (rarely metastasizing) fibroblastic and myofibroblastic tumors.[6] WHO, 2020, classifies HGMS (preferred name: undifferentiated pleomorphic sarcoma) as a soft tissue tumor in the category of tumors of uncertain differentiation.[7] This article follows the WHO classification: here, LGMS includes IGMS but not HGMS which is a more aggressive and metastasizing tumor than LGMS[8] and consists of cells of uncertain origin.[4]
| Low-grade myofibroblastic sarcoma | |
|---|---|
| Other names | Intermediate-grade myofibroblastic sarcoma is now regarded as a low-grade myofibroblastic sarcoma |
| Symptoms | Tumor, sometimes painful |
| Complications | Post-surgical recurrences; uncommonly metastasizes |
| Usual onset | All ages |
| Causes | Unknown |
| Treatment | Surgical removal of tumor |
| Prognosis | Guarded |
| Deaths | Uncommon |
LGMS tumors are typically painless lesions that develop in: 1) the subcutaneous tissues, i.e. the lowermost layer of the skin;[9] 2) submucosa, i.e. the thin layer of tissue lying just below the mucous membranes that line passageways such as the gastrointestinal, respiratory, genitourinary tracts;[8] 3) muscles; and 4) bones.[9] They most often develop in middle-aged adults (average: 40 years old) but have been diagnosed in all age-groups.[8] These tumors often recur at the sites of their surgical removal and may metastasize to nearby lymph nodes and distant tissues.[10]
LGMS's are commonly treated by surgical removal of the tumor along with all its cells, which if not removed increase the probability that the tumor will recur at the site of its removal.[1] LGMS tumors typically show little or no sensitivity to radiotherapy and chemotherapy treatments.[11]
Presentation
editLGMS present as single tumors that ranged in size from 0.4 to 24.0 cm in three literature review studies.[1][4][12] In another study, 103 individuals diagnosed with LGMS were aged 2–75 years (median: 43 years) with 12.6% < 18 years, 65.1% 18–60 years, and 22.3% >60 years old. Eighty-two percent of their LGMS tumors were located in soft tissues (28.2% in mucous membranes, 21.8% in muscle, 19.2% in skin, and 12.9% in other soft tissues) and 18% were in bone. Overall, 51.5% of their tumors were in the head and neck areas (most commonly the tongue, followed by the larynx, gums, mandible, face, skull, and ear canal), 25.2% were in the trunk, and 23.3% were in an arm or leg. Bone tumors were located in the femurs, mandible, maxilla, tibias, or in one case each the hard palate and sacrum.[1] In other reports, the tumors occurred in the oral mucosa, lip,[13] groin, small intestine, greater omentum or lesser omentum (which omentum not defined),[2] heart,[10] eye socket (in an 11 month old infant),[14] and chest wall/breast.[15] While typically presenting as slow growing, painless masses, some individuals have presented with increasingly painful subcutaneous or submucosal masses (16 of 50 individuals reported pain in one retrospective study).[1] Rare cases of submucosal LGMS tumors have presented with more serious symptoms such as partial bowel obstructions due to intrabdominal LGMS tumors,[2][10] shortness of breath and palpitations due to a LGMS tumor in the heart,[16] difficulty in swallowing and breathing due to a laryngeal LGMS tumor,[17] and abdominal pain due to a pancreas LGMS tumor.[18] A study of 96 individuals presenting for the first time with LGMS found that 51.0% had local disease, 25.0% had regional disease, 15.6% had metastases to the local lymph nodes, and 8.3% had distant metastases.[11] (In the study 103 individuals, the distant metastasis rate was 4.4%.[1]) Metastasis have been reported to develop in various sites including the lungs,[2][11] pleura, lymph nodes, bones, thoracic cavity, abdominal cavity, peritoneum,[10] heart,[11] brain, and spinal cord.[19]
Pathology
editMicroscopic histopathological analyses of hematoxylin and eosin stained LGMS tissues generally show bundles of atypical spindle-shaped cells in a variably hyalinized (i.e. glassy appearing) stromal background containing collagen fibers.[9] The tumors are not encapsulated and commonly infiltrate adjacent fibrous, fat, or skeletal muscle tissues.[4] (The tumor's spindle-shaped cells may infiltrate between individual skeletal muscle fibers[2] to create a characteristic checkerboard pattern.[9]) LGMS tissues commonly have small or more extensive foci of epithelioid (i.e. epithelial-like) cells with a polygonal shape.[20] In a minority of cases, the tumor tissues have scattered mast cells, sites of numerous neutrophils,[2] and areas of necrosis (i.e. dead or dying cells).[4]
Immunohistochemical analyses find that the LGMS tumors' spindle-shaped cells commonly express ACTA2 (also known α-smooth muscle actin) and desmin (i.e. an intermediate filament protein found in all muscle forms including smooth muscle) proteins,[8] with some tumors composed of cells expressing both of these proteins and other tumors composed of cells expressing only one of them.[8][9][13][20] The tumor cells often express vimentin and SMARCB1 (also termed INI-1 and SNF5) proteins but typically fail to express CD34, S-100, CD34, STAT6, CD68, CD56, cytokeratin, ERG, β-catenin, or myogenin proteins.[14][13] The epithelioid, polygonal-shaped cells express cytokeratin and TP63 proteins.[20]
Chromosome and gene abnormalities
editVarious chromosome abnormalities have been found in the tumor cells of a few LGMS cases. A ring chromosome and/or giant marker chromosome, which commonly occur in the cells of various mesenchymal tumors,[21] were found in one case of LGMS.[2] In addition, these tumor cells may, in rare cases, contain copy number variations such as gains in the genetic material on the short (i.e. 'p') arm of chromosomes 1, 12, and 5 and losses in genetic material on the long (i.e. 'q') arm of chromosome 15.[14] These chromosome abnormalities are considered non-specific.[2][14] Analysis of LGMS tumor cells for chromosome and gene abnormalities has not yet been helpful in understanding or diagnosing the disorder.[14]
Diagnosis
editLGMS should be suspected in cases presenting as nodular masses composed of spindle-shaped cells combining fibroblast and smooth muscle cell features that are arranged in bundles and express α-smooth muscle actin[20] and/or desmin proteins[9] but not vimentin, S-100, CD34 or other marker proteins cited in the previous section. Spindle-shaped cell infiltrations between individual skeletal muscle fibers that form a checkerboard pattern[9] and the presence of foci containing epithelioid, polygonal cells that express cytokeratin and TP63 proteins[20] are also indicative of a LGMS tumor.
Treatment and prognosis
editPast treatments for LGMS, including surgery, radiotherapy, and chemotherapy, have not been systematically investigated nor validated.[8] Currently, the primary and most common treatment for non-metastatic LGMS is surgical resection with, where possible, removal of all tumor cells in order to reduce this tumor's recurrence rate (e.g. ~27% and ~38% in two different studies).[1] Following this surgery, individuals should undergo long-term observation to check for post-surgical recurrences and the uncommon instances of metastases.[8][10] One study suggested that tumor cells with high rates of proliferation, tumors containing areas of necrosis, tumor sizes >10 cm in largest diameters, and deep-seated tumors are at higher risks for metastasizing.[17]
Radiotherapy and chemotherapy have been used with or without surgical resections to treat cases in which tumor resections were later found to leave tumor cells behind, in which tumors could not be safely resected, and in which metastases were present.[1][2][11] In the study of 96 individuals presenting with LGMS tumors for the first time, 89.6% received surgical treatment, 29.2% received radiation treatment, and 20% received chemotherapy. The study concluded that radiotherapy and chemotherapy had limited effects on survival and therefore should not be routinely used in LGMS, especially for cases in which all tumor cells are removed.[11] These results and conclusions agree with previous reports finding that LGMS tumors are insensitive to radiotherapy and chemotherapy.[10] Nonetheless, there have been case reports that local radiotherapy may allow longer survival periods[10] and may, in select cases, be useful for treating LGMS.[11] A similar situation exists with chemotherapy: some reports recommend chemotherapy as a potential treatment strategy, particularly when complete excision of the tumor is not possible, when the tumor is highly invasive, and/or when the tumor has spread to lymph nodes and/or distant tissues.[11] There are case reports where chemotherapy following surgical excision may have been useful in prolonging progression-free survival, for example, in an individual with a pancreatic LGMS tumor (treatment regimen: ifosfamide, pirarubicin, and nedaplatin).[18] Further studies are needed to define the usefulness of radiation therapy and chemotherapy in LGMS.[10]
The majority of studies on the prognosis of patients treated for LGMS have focused on short-term (i.e. one-year) follow-up times.[10] One study of 49 patients (age range: 29.5–64.5; average age: 46.2 years; median age: 51.0 years) treated for LGFS reported overall survival percentages at 3 and 5 years of 75.0% and 71.6%, respectively. Their disease-specific survival (i.e. excluding deaths from causes unrelated to LGMS) at 3 and 5 years after treatment were 80.0% and 76.3%, respectively. These patients were treated with surgery in 93.9% of cases and radiotherapy in 26.5% of cases but no patients had lymph node metastasis and only 1 case had distant metastases (the presence of lymph node and distant tissue metastasis was unknown in 8 patients).[12] The study of 96 individuals treated for LFMS reported 1, 3, 5, and 10-year disease-specific survival percentages of 88%, 77%, 70%, and 59%, respectively. Patient age >60 years was the only factor that clearly reduced survival times in this study (disease specific survival times for patients 60 years old or younger and >60 years were 167.1 and 92.5 months, respectively).[11]
References
edit- ^ a b c d e f g h Yonezawa H, Yamamoto N, Hayashi K, Takeuchi A, Miwa S, Igarashi K, Langit MB, Kimura H, Shimozaki S, Kato T, Morinaga S, Araki Y, Asano Y, Ikeda H, Nojima T, Tsuchiya H (December 2020). "Low-grade myofibroblastic sarcoma of the levator scapulae muscle: a case report and literature review". BMC Musculoskeletal Disorders. 21 (1): 836. doi:10.1186/s12891-020-03857-3. PMC 7731512. PMID 33302922.
- ^ a b c d e f g h i Mentzel T, Dry S, Katenkamp D, Fletcher CD (October 1998). "Low-grade myofibroblastic sarcoma: analysis of 18 cases in the spectrum of myofibroblastic tumors". The American Journal of Surgical Pathology. 22 (10): 1228–38. doi:10.1097/00000478-199810000-00008. PMID 9777985.
- ^ Zhao KY, Yan X, Yao PF, Mei J (September 2021). "Malignant fibrous histiocytoma of the bone in a traumatic amputation stump: A case report and review of the literature". World Journal of Clinical Cases. 9 (26): 7930–7936. doi:10.12998/wjcc.v9.i26.7930. PMC 8462244. PMID 34621848.
- ^ a b c d e Fisher C (September 2004). "Myofibrosarcoma". Virchows Archiv. 445 (3): 215–23. doi:10.1007/s00428-004-1038-9. PMID 15173943. S2CID 220565385.
- ^ Zhao R, Wang J, Zhang H, Chi Y, Bi N (October 2020). "High-grade myofibroblastic sarcoma of the pleura: A case report and literature review". Thoracic Cancer. 11 (10): 3011–3014. doi:10.1111/1759-7714.13613. PMC 7529570. PMID 32815307.
- ^ Sbaraglia M, Bellan E, Dei Tos AP (April 2021). "The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives". Pathologica. 113 (2): 70–84. doi:10.32074/1591-951X-213. PMC 8167394. PMID 33179614.
- ^ Choi JH, Ro JY (January 2021). "The 2020 WHO Classification of Tumors of Soft Tissue: Selected Changes and New Entities". Advances in Anatomic Pathology. 28 (1): 44–58. doi:10.1097/PAP.0000000000000284. PMID 32960834. S2CID 221862064.
- ^ a b c d e f g Mulay K, Sen M, Honavar SG (November 2020). "Limbal, low-grade myofibroblastic sarcoma: Case report and literature review". Indian Journal of Ophthalmology. 68 (11): 2538–2540. doi:10.4103/ijo.IJO_2410_20. PMC 7774147. PMID 33120683.
- ^ a b c d e f g Baranov E, Hornick JL (March 2020). "Soft Tissue Special Issue: Fibroblastic and Myofibroblastic Neoplasms of the Head and Neck". Head and Neck Pathology. 14 (1): 43–58. doi:10.1007/s12105-019-01104-3. PMC 7021862. PMID 31950474.
- ^ a b c d e f g h i Wu X, Guo L, Li S, Zheng Y, Fan B, Zhou C (January 2020). "Low-grade myofibroblastic sarcoma with abdominal pain, a stuffy nose, hearing loss, and multiple cavity effusion: a case report and literature review". The Journal of International Medical Research. 48 (1): 300060519895661. doi:10.1177/0300060519895661. PMC 7114293. PMID 31975633.
- ^ a b c d e f g h i Xu Y, Xu G, Wang X, Mao M, Wu H, Baklaushev VP, Chekhonin VP, Peltzer K, Wang G, Zhang C (February 2021). "Is there a role for chemotherapy and radiation in the treatment of patients with low-grade myofibroblastic sarcoma?". Clinical & Translational Oncology. 23 (2): 344–352. doi:10.1007/s12094-020-02425-4. PMID 32607812. S2CID 220286531.
- ^ a b Chan JY, Gooi Z, Wong EW, Ng SK, Tong MC, Vlantis AC (January 2017). "Low-grade myofibroblastic sarcoma: A population-based study". The Laryngoscope. 127 (1): 116–121. doi:10.1002/lary.26146. PMID 27377169. S2CID 9627754.
- ^ a b c Jayasooriya PR, Athukorala C, Attygalla M, Mendis BR, Lombardi T (January 2021). "Low-Grade Myofibroblastic Sarcoma of the Oral Cavity: A Report of Three Cases Illustrating an Emerging Disease in Children". Dermatopathology. 8 (1): 1–9. doi:10.3390/dermatopathology8010001. PMC 7838777. PMID 33401376.
- ^ a b c d e Tang L, Xu H, Gao H, Yang H, Chen S, Zhang P (November 2020). "Primary low-grade myofibroblastic sarcoma: A rare case report of this tumor in the orbit and literature review". European Journal of Ophthalmology. 32 (2): NP67–NP70. doi:10.1177/1120672120970392. PMID 33198493. S2CID 226988997.
- ^ Katalinic D, Santek F (May 2017). "Giant low-grade primary myofibroblastic sarcoma of the posterior chest wall". World Journal of Surgical Oncology. 15 (1): 96. doi:10.1186/s12957-017-1167-7. PMC 5415824. PMID 28468630.
- ^ Oylumlu M, Yildiz A, Ercan S, Oylumlu M, Davutoglu V (2014). "Cardiac metastasis of a low-grade myofibroblastic sarcoma". Echocardiography (Mount Kisco, N.Y.). 31 (1): E1–4. doi:10.1111/echo.12370. PMID 24111760. S2CID 7195357.
- ^ a b Nair NP, Kaushal D, Rao M, Soni K, Vaithankalath S (October 2020). "Evaluation and Management of an Uncommon Tumor of the Larynx: A Case Report and Literature Review of Laryngeal Low-Grade Myofibroblastic Sarcoma". Cureus. 12 (10): e11072. doi:10.7759/cureus.11072. PMC 7676948. PMID 33224666.
- ^ a b Peng L, Tu Y, Li Y, Xiao W (September 2018). "Low-grade myofibroblastic sarcoma of the pancreas: A case report and literature review". Journal of Cancer Research and Therapeutics. 14 (Supplement): S796–S799. doi:10.4103/0973-1482.183551. PMID 30249907. S2CID 52814348.
- ^ Lehoczky T, Halasy M (May 1966). "[Depression and biochemistry--Results of Nuredal therapy]". Orvosi Hetilap (in Hungarian). 107 (18): 819–23. PMID 5328880.
- ^ a b c d e Magro G, Salvatorelli L, Puzzo L, Piombino E, Bartoloni G, Broggi G, Vecchio GM (December 2019). "Practical approach to diagnosis of bland-looking spindle cell lesions of the breast". Pathologica. 111 (4): 344–360. doi:10.32074/1591-951X-31-19. PMC 8145669. PMID 31965112.
- ^ Nishio J, Aoki M, Nabeshima K, Iwasaki H, Naito M (August 2012). "Characterization of giant marker and ring chromosomes in a pleomorphic leiomyosarcoma of soft tissue by spectral karyotyping". Oncology Reports. 28 (2): 533–8. doi:10.3892/or.2012.1835. PMID 22641359.